Summarized by Masters of Longevity from Longevity Technology.
Fractyl widened its U.S. patent estate for the Revita DMR system as it advances toward a planned FDA De Novo submission.
Key Takeaways
- Fractyl has expanded patents for the Revita DMR system.
- The filings are tied to a planned FDA De Novo submission.
- The patent growth complements positive six-month REMAIN-1 results.
